Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

NAL HIGHLIGHTS

On September 10, 2008, Vanda met with the U.S. Food and Drug Administration (FDA) to discuss the not-approvable action letter that the FDA issued to Vanda on July 25, 2008 regarding iloperidone. The FDA asked Vanda to provide a complete response to the not-approvable letter highlighting arguments made during the meeting. Vanda expects to submit the complete response within the next few weeks. The timing or outcome of any FDA review of the response is uncertain at this time.

Vanda has suspended all commercial and development activities pending further review. Vanda has also reduced its cash burn and is reviewing a number of options to further reduce expenses and cash burn.

FINANCIAL DETAILS

Operating Expenses. Third quarter 2008 R&D expenses, primarily consisting of salaries and related costs of R&D personnel, stock-based compensation, and the costs of consultants, materials and supplies associated with clinical trials and research initiatives, totaled $3.8 million, compared to $5.5 million in the second quarter of 2008 and $13.9 million in the third quarter of 2007. The decrease in R&D expenses in the third quarter of 2008 relative to the second quarter of 2008 is primarily attributable to lower costs in the Phase III tasimelteon chronic primary insomnia clinical trial for which Vanda reported top-line results in June of 2008. The decrease in R&D expenses in the third quarter of 2008 relative to the third quarter of 2007 is primarily attributable to lower clinical trial costs in the third quarter of 2008 compared to the costs from trials conducted in the third quarter of 2007 and the $5.0 million milestone charge recorded in the third quarter of 2007 resulting from the submission of the NDA for iloperidone.

-- General and administrative (G&A) expenses totaled $7.4 million in the third quarter of 2008, compared to $8.5 million in the second quarter of 2008 and $9.6 million in the third quarter of 2007. The decrease in
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade hypothermic storage and cryopreservation freeze ... and tissues  ("BioLife" or the "Company"), today announced that it ... 4, 2015 (the "Annual Meeting"). Because the expected ...
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ...
(Date:12/24/2014)... report expects global cell isolation and expansion market to grow ... data about the vital drivers, restraints, trends, opportunities, strategies and ... http://bit.ly/1yUxy0T , According to the report, the global ... impressive CAGR during near future. It expects this growth to ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... May 13 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ... and products in the People,s Republic of China,announced that ... and Exchange Commission (SEC) that, if declared effective by ... to time, up to $100 million,of its common stock ...
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ) a ... in the People,s Republic of China,announced that it intends ... March 31, 2008, on Thursday, June 12, 2008., ... Thursday, June,12, 2008 at 9:00 a.m. Eastern Time to ...
... Patients Shipped in the Quarter ... ... BEDFORD, Mass., May 13 Insulet Corporation,(Nasdaq: PODD ), a ... today announced financial results for,the first quarter ended March 31, 2008., ...
Cached Biology Technology:Chindex International Announces Shelf Registration, Related Strategy and Guidance 2Chindex International Announces Shelf Registration, Related Strategy and Guidance 3Chindex International Announces Shelf Registration, Related Strategy and Guidance 4Chindex International Announces Shelf Registration, Related Strategy and Guidance 5Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 3Insulet Reports First Quarter 2008 Results 2Insulet Reports First Quarter 2008 Results 3Insulet Reports First Quarter 2008 Results 4Insulet Reports First Quarter 2008 Results 5Insulet Reports First Quarter 2008 Results 6Insulet Reports First Quarter 2008 Results 7
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the ... Security Systems Market" report to their offering. ... perimeter security market is estimated to grow at a CAGR ... holds a larger share in this market, Canada ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced the ... Button Synaptics Fingerprint Sensor Technology Analysis" report to ... Based on a totally different sensing technology ... time a fingerprint sensor in its product. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... has allowed biologists to identify two critical genes responsible for ... cause of infant mortality and death in people born with ... November 3 issue of the open access journal PLoS ... Research Institute in La Jolla, Calif., and the University of ...
... Zoo Global Wildlife Conservancy scientists have taken a tremendous ... achieved through the first successful establishment of cell cultures ... gopher frog. A method called "tissue piecing" and immediate ... samples that can later be processed in a laboratory. ...
... Group at the Nano-Science Center and the Department of Neuroscience ... hard to characterise and test how molecules react, combine together ... development of new medicine. The researchers, breakthrough, as ... that they are able to work with reactions that take ...
Cached Biology News:Biologists use flies and mice to get to the heart of Down syndrome 2Biologists use flies and mice to get to the heart of Down syndrome 3San Diego Zoo scientists establish cell cultures of endangered frog 2Nano-tech makes medicine greener 2
Replacement Parts for Electrophoresis Apparatus...
Histone H2A Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Detects ~14 kDa Histone H2A. It does not cross-react with other Histones. Reacts with human/mouse/rat. Performs w...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
... Clone/PAD: PS603. Immunogen: Synthetic ... surrounding the phosphorylated Ser603 residue ... Specificity: Specific for synapsin I ... 3). Reactivity: Rat (positive ...
Biology Products: